Researchers at the University of São Paulo have developed an artificial saliva using CANECPI-5, a lab-modified sugarcane protein, that binds directly to tooth enamel to shield it from acid erosion and bacterial decay. The innovation holds particular promise for head and neck cancer patients who lose salivary function after radiation therapy, and could reshape preventive care protocols across Canadian dental practices.
As of April 2026, there is no commercially available product specifically designed to prevent severe cavities in patients who have undergone head and neck radiation therapy. That gap may be closing. A study published in the Journal of Dentistry (Volume 163, Article 106176) details how a team of international researchers created a sugarcane-derived protein coating that functions as a next-generation artificial saliva — one that does far more than simply moisturize the oral cavity.
What Is CANECPI-5 and How Does It Work?
CANECPI-5 is a lab-modified version of a cysteine proteinase inhibitor found naturally in sugarcane. Unlike conventional saliva substitutes that wash away within minutes, CANECPI-5 binds directly to tooth enamel. This gives the coating unusual staying power, allowing it to form a persistent shield against the acids produced by oral bacteria and those introduced through food, beverages, and gastric reflux.
The protein operates on two fronts simultaneously. First, it reduces enamel demineralization — the chemical process by which acids strip calcium and phosphate from tooth surfaces, creating the conditions for cavities. Second, it regulates bacterial populations in the mouth, reducing counts of decay-causing organisms without the broad-spectrum antimicrobial effects that disrupt the oral microbiome.
Pro Tip: For dental professionals in Toronto and the Greater Toronto Area managing patients undergoing radiation therapy, monitoring salivary flow rates using sialometry at each recall appointment helps identify the transition point where preventive interventions become necessary.
The Research Behind the Breakthrough
The study was led by the Bauru School of Dentistry at the University of São Paulo (FOB-USP) in Brazil, with international collaboration from the Federal University of São Carlos (Brazil), the University of California San Francisco, and Yonsei University College of Dentistry in South Korea.
Testing demonstrated that CANECPI-5 performs best when combined with fluoride and xylitol. The formulation reduced surviving bacterial counts and slowed enamel mineral loss compared to untreated samples. When benchmarked against a commercial saliva substitute and a standard antibacterial rinse, the combined CANECPI-5 formulation matched or outperformed both comparison groups.
The researchers are now scaling production and testing multiple delivery formats, including mouthwash, gel, and an orodispersible film that dissolves on the tongue. The protein has been patented, signalling a clear path toward commercialization.
Why This Matters for Canadian Dental Practices
Xerostomia — chronic dry mouth — affects a significant proportion of the Canadian population beyond cancer patients. According to the Canadian Dental Association (CDA), dry mouth is a common side effect of more than 400 medications, including antidepressants, antihistamines, blood pressure medications, and diuretics. Many older adults in Ontario and across Canada manage multiple prescriptions that collectively suppress salivary output.
Current treatment options available in Canada are limited. Existing artificial saliva products — typically carboxymethylcellulose or mucin-based formulations — provide temporary moisture but do not actively protect enamel or modulate bacterial activity. A product that combines moisturizing properties with genuine protective function would fill a real clinical gap.
For practices in Toronto, Mississauga, Brampton, Markham, and across the GTA, the clinical implications extend to everyday preventive care. Patients on polypharmacy regimens, those with Sjögren's syndrome, and individuals managing gastroesophageal reflux disease (GERD) all present with accelerated enamel erosion. A bio-adhesive protective coating could significantly reduce the restorative burden on these patients.
Pro Tip: When counselling patients with medication-induced dry mouth, recommend they sip water throughout the day, use xylitol-containing products, and schedule more frequent recall intervals (every 3-4 months rather than 6) until salivary function stabilizes.
Regulatory Pathway and Timeline
Before any CANECPI-5 product reaches Canadian dental practices, it will need to navigate Health Canada's regulatory approval process. Depending on classification — whether as a natural health product, a medical device, or a drug — the pathway could range from 12 to 36 months after the manufacturer submits an application.
The Royal College of Dental Surgeons of Ontario (RCDSO) does not typically regulate specific products, but provincial guidelines around the use of novel preventive agents may apply. Dental professionals should watch for Health Canada Drug Product Database updates and CDA position statements as the product moves through clinical trials.
The Broader Context: Preventive Dentistry Is Evolving
This research sits within a larger trend reshaping preventive dentistry in 2026. Silver diamine fluoride (SDF) gained mainstream acceptance over the past three years as a non-invasive caries management tool. Bioactive glass-containing toothpastes and remineralizing varnishes have expanded the preventive toolkit. CANECPI-5 represents the next logical step: a biologically active coating that actively defends enamel rather than passively delivering minerals.
For Ontario dental practices already incorporating minimally invasive approaches, a bio-adhesive enamel protectant would complement existing protocols for high-caries-risk patients. The combination of fluoride varnish at recall appointments, xylitol recommendations for home care, and an enamel-binding protein barrier could create a genuinely comprehensive preventive strategy.
Frequently Asked Questions
Q: What is CANECPI-5 and how does it protect teeth?
CANECPI-5 is a lab-modified sugarcane protein that binds directly to tooth enamel, creating a persistent shield against acid erosion and bacterial decay. Unlike conventional artificial saliva products that wash away quickly, CANECPI-5 adheres to the tooth surface and actively reduces demineralization while regulating harmful bacterial populations in the mouth.
Q: When will sugarcane-based artificial saliva be available in Canadian dental practices?
The CANECPI-5 protein has been patented and researchers are currently scaling production and testing delivery formats including mouthwash, gel, and orodispersible film. Before reaching Canadian practices, the product must receive Health Canada regulatory approval, which could take 12 to 36 months after submission depending on product classification.
Q: Which patients would benefit most from CANECPI-5 artificial saliva?
Head and neck cancer patients who lose salivary gland function after radiation therapy stand to benefit most, as no dedicated product currently exists for preventing severe post-radiation cavities. Beyond oncology patients, individuals with medication-induced dry mouth, Sjögren's syndrome, and GERD-related enamel erosion could also benefit from a bio-adhesive enamel protectant.
EBIKO Dental will continue monitoring developments in preventive dental products and technologies. For the latest dental industry news relevant to Canadian practices, visit ebiko.ca.